Cetaphil, Alastin and Restylane skin care products, owned by Galderma, are pictured in the company’s offices in Lausanne, Switzerland, March 13, 2024. REUTERS
ZURICH, April 23 (Reuters) – Swiss skincare firm Galderma on Thursday said first-quarter sales jumped 25.5% in constant-currency terms to $1.47 billion, and signalled it would be able to manage the impact of U.S. tariffs in 2026.
The Zug-based company’s results showed that brisk business in the United States powered growth in the January-March period, with sales there leaping 41.5% year-on-year.
“Based on the strong start to the year, the guidance is increasingly being de-risked with confidence to navigate a volatile environment,” Galderma said in a statement.
Galderma, which was listed on the Swiss stock exchange just over two years ago, said its exposure to U.S. tariffs is expected to remain “manageable” this year.
Alongside tariffs assumed for its Sculptra and Restylane injectables, the firm’s confirmed full-year guidance also factors in the expected impact of a recent U.S. announcement on imports of pharmaceuticals and pharmaceutical ingredients.
Writing by Dave Graham Editing by Ludwig Burger
